Safety and Efficacy of Tenofovir DF in HIV-1 Infected Adolescents Failing Their Current Antiretroviral Therapy

PHASE3CompletedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

September 30, 2008

Study Completion Date

December 31, 2013

Conditions
HIV Infections
Interventions
DRUG

Tenofovir DF

Tenofovir DF 300-mg tablet, administered orally, daily + OBR

DRUG

Placebo

Tenofovir DF Placebo administered orally, daily + OBR

Trial Locations (18)

Unknown

Faculdade de Medicina - UFMG, Belo Horizonte - MG

Santa Casa de Belo Horizonte, Belo Horizonte - MG

Hospital e Maternidade Celso Pierro, Campinas - SP

Universidade Estadual de Campinas - UNICAMP, Campinas - SP

Centro de Doenças Infecciosas e Parasitárias, Campo Grande - MS

Hospital das Clinicas da Universidade Federal do Parana - UFPR, Curitiba - PR

Hospital Infantil Joana de Gusmão, Florianópolis - SC

Hospital Municipal Sao Jose, Joinville - SC

Hospital Materno Infantil Professor Fernando Figueira- IMIP, Recife

Hospital dos Servidores do Estado, Rio de Janeiro

Hospital Geral de Nova Iguacu Ambulatorio de DST e AIDS, Rio de Jeneiro

Hospital Guilherme Alvaro, Santos

Instituto da Crianca do Hospital das Clinicas da FMUSP Depto de Pediatria, Sao Paulo - SP

Instituto de Infectologia Emilio Ribas, Sao Paulo - SP

NEIMPE - Dept of Pediatrics Hospital das Clinicas FMRP-USP, São Paulo

Universidade Federal de Sao Paulo, Vila Clementino

Hospital Infantil Nossa Senhora da Gloria Servico de Infectologia Pediatria, Vitoria - ES

Hospital del Nino, Panama City

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY